MabThera nabs NICE nod for leukemia

The U.K.'s cost-effectiveness watchdog has recommended Roche's top-selling cancer drug MabThera as a first line treatment for the most common form of adult leukemia. NICE recommends that the National Health Service pay for MabThera treatment only in combination with two specific chemo drugs. Report

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.